New to The Street Airs Episode #655 Tonight on Bloomberg at 6:30 PM EST Featuring Synergy CHC (Focus Factor(R), Flat Tummy Tea, Keto + ACV), Health In Tech, Skip Barber Racing School, LightPath Technologies, and Roadzen
NEW YORK CITY, NEW YORK / ACCESS Newswire / May 10, 2025 / New to The Street, one of the nation's longest-running and most trusted business television brands, will air Episode #655 tonight, Saturday, May 10, 2025, at 6:30 PM EST on Bloomberg Television as sponsored programming.
This episode features five forward-thinking companies making an impact in their sectors:
Episode 655 is presented with sponsorship from:
'This episode is a showcase of innovation across wellness, insurance, racing, optics, and AI,' said Vince Caruso, Founder and CEO of New to The Street. 'We're proud to present brands like Focus Factor® and Flat Tummy, alongside disruptive technology companies reshaping their industries.'
The episode is hosted by Jane King, financial journalist and anchor known for her insightful interviews and market coverage.
Broadcast Details:
Show Title:New to The Street
Episode #: 655
Air Date: Saturday, May 10, 2025
Time: 6:30 PM EST
Network: Bloomberg Television (as sponsored programming)
Streaming: YouTube.com/NewToTheStreetTV - The fastest-growing financial channel with over 2.47 million subscribers
For media inquiries, please contact:
Monica Brennan
Director of Communications
[email protected]
About New to The Street
New to The Street is a leading U.S. business television series that profiles innovators and industry disruptors weekly across Bloomberg, Fox Business, and the New York Stock Exchange. With a 17-year track record and a multimedia approach combining sponsored TV, earned media, social content, and billboard visibility, New to The Street offers companies 'Opportunities to Consider™.' Its official YouTube channel, New to The Street TV, is the fastest-growing financial channel with over 2.47 million subscribers and expanding global viewership.
SOURCE: New To The Street
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Got $1,000? 2 High-Yield Healthcare Stocks to Buy and Hold Forever
Key Points The average healthcare stock is yielding a fairly modest 1.8% these days. Medtronic has a historically high yield and a long history of raising its dividend. Alexandria Real Estate's yield is ultra-high, and it has plenty of dividend coverage. 10 stocks we like better than Medtronic › The average healthcare stock has a yield of just 1.8%, which isn't much to write home about today. You can do much better than that with Medtronic (NYSE: MDT), currently yielding 3%, or if you're really income-hungry, Alexandria Real Estate Equities (NYSE: ARE), now at 6.9%. Here's why these two high-yield healthcare stocks could be buy-and-hold candidates for your income portfolio right now. Medtronic is moving in the right direction A $1,000 investment in Medtronic will get you around 10 shares of the medical device giant. It has operations in the cardiovascular, neuroscience, medical-surgical, and diabetes arenas, and is a major player in every niche in which it operates. It also has a long history of success that's highlighted by the company's 48-year streak of annual dividend increases, which puts it just two years away from Dividend King status. That dividend streak is really important because it shows that Medtronic knows how to survive through both good and bad times. Indeed, a company can't create a record like that without having successfully muddled through a few rough patches. The 3% dividend yield is historically high today, which signals that Medtronic is going through another rough patch. What's happening right now, however, isn't unusual. Medtronic's business is heavily dependent on research and development. R&D is notoriously lumpy, and recent years haven't been great for new product launches. But new products are starting to get introduced, which should help boost growth. Meanwhile, costs have become an issue. It's normal for a large company to experience bloat, and Medtronic is looking to slim down and refocus around its most profitable businesses; the next big move is the spinoff of its diabetes business in 2026. The move is expected to be accretive in the first year, highlighting management's focus on profitability. In other words, Medtronic is doing what it should be doing -- and that is what it has long done as a business. If you have a buy-and-hold mentality, putting $1,000 to work in Medtronic today could be a great long-term investment choice. Alexandria is an industry-leading healthcare landlord You can buy around 12 shares of Alexandria Real Estate Equities with $1,000. It's a real estate investment trust (REIT) that focuses on owning medical offices. But that description doesn't do it justice, because those medical offices are highly specialized around medical research. They're vastly different from doctors' offices, given the technology needed to support healthcare research and development. Alexandria has long focused on building clusters -- a number of buildings located near each other -- in areas where medical research is a major industry. That helps with costs, and also helped to solidify the REIT as a leading property owner in its chosen niche. That said, Alexandria is in a bit of a transition period right now, as it looks to slim down to its best assets amid a broader slowdown in the medical-office space. A few large move-outs have also hampered results, with occupancy down to roughly 91% at the end of the second quarter of 2025, from about 95% at the end of 2024. Investors are worried, which isn't unreasonable, since adjusted funds from operations (FFO) per share fell slightly year over year in the second quarter. Still, the $2.33 per share in adjusted FFO is more than enough to cover the $1.32 per share in quarterly dividends. While it's true that office space requires more cash investment than many other property types, there is material leeway for adversity for Alexandria. And given that the dividend has been increased annually for 15 straight years, it seems highly likely that the board will look to support the dividend through this weak patch. Note, too, that the balance sheet is in very strong shape and the company doesn't have any material near-term debt maturities on the horizon. If you don't mind buying when others are fearful, this REIT looks like an attractive income opportunity. The right time to buy is often the hard time to buy It's easy to buy stocks that everybody loves, but just following the crowd can lead to bad investment choices. That's why it often pays to go down a less crowded path, buying well-run businesses when they're facing hard times. That's exactly the case with both Medtronic and Alexandria Real Estate Equities today. History suggests that both have a good chance of breaking out of their current funk. And that makes them strong buy-and-hold investment choices for long-term dividend investors. Should you buy stock in Medtronic right now? Before you buy stock in Medtronic, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Medtronic wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $654,781!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,076,588!* Now, it's worth noting Stock Advisor's total average return is 1,055% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Reuben Gregg Brewer has positions in Medtronic. The Motley Fool has positions in and recommends Alexandria Real Estate Equities. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. Got $1,000? 2 High-Yield Healthcare Stocks to Buy and Hold Forever was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
15 minutes ago
- Yahoo
Post Malone apart of new SKIMS campaign
Post Malone has joined SKIMS, with founder Kim Kardashian describing the partnership as a "perfect fit".
Yahoo
15 minutes ago
- Yahoo
Downsize me: McDonald's plans to cut combo meal prices after complaints
McDonald's is slashing its combo meal prices after customers had a beef with the burger giant's rising prices. For eight popular combo meals, the fast-food chain will offer prices 15 percent below the sum of the items sold separately, the Wall Street Journal first reported. A combo meal that now costs $10 could soon cost $8.50. 'Customers are telling us they need more of the everyday value and affordability that defines the McDonald's brand,' Joe Erlinger, president of McDonald's USA, told the company after it released a quarterly report this month, according to the outlet. Customers will see the changes as soon as this fall. In September, McDonald's will offer $5 Sausage Egg McMuffin and $8 Big Mac meals; in November, Sausage, Egg and Cheese McGriddle and 10-piece Chicken McNuggets meals will go for $5 and $8. To add to the delicious new prices, McDonald's is reintroducing the 'Extra Value Meals' branding, which includes $5 breakfast and $8 Big Mac and McNugget combo-meal specials, the Journal reported. The chain first launched 'Extra Value Meals' — bargain combo meals — in 1991, but stopped marketing them as such during the Covid-19 pandemic, the outlet reported. The Independent has asked McDonald's for more information. The move comes amid complaints from customers about the fast-food chain's rising prices. A viral 2023 tweet showed a Big Mac combo meal costing nearly $18, rocking the internet. The company called that price tag 'an exception' but the complaints have continued to roll in across social media. 'McDonald's used to be the escape when rent was due and payday was far, one X user groaned earlier this month. 'Now a 'value meal' is $14 and the value is gone…When people can't even afford McDonald's, the economy is already broken.' Another reminisced last week: 'Remember when McDonald's used to be cheap?' Yet another expressed disappointment, writing this month: 'How is a medium french fry at McDonald's $3.39? Geez, that's ridiculous.' '$26.60 for a breakfast for two at McDonald's?' another wrote, adding 16 question marks. 'INSANITY!!! This is Trump and Elon's America!' While President Donald Trump and his former head of the Department of Government Efficiency may not be entirely to blame for the climbing prices, McDonald's first quarter earnings report showed a dip in sales, which fast-food chain executives chalked up to 'economic uncertainty.' Sales grew during the second quarter, but the fast-food giant noticed a decline in low-income diners. "There is a lot of anxiety and unease with that low-income consumer," Kempczinski said during a call this month, citing tariffs and a slowdown in real income growth. 'The single biggest driver of what shapes a consumer's overall perception of McDonald's value is the menu board,' he added. McDonald's combo meals priced at $10 or more could be deterring lower-income customers. The average large Big Mac meal costs $10.53, according to The Journal. But that price tag depends on the location, with the prices range from $5.69 to $18.99, according to data seen by the outlet from market-research firm Technomic. To help appeal to these customers, the chain debuted a new $5 meal deal last as part of its 'McValue' menu. McDonald's CFO Ian Borden at the time attributed the deal as driving traffic 'particularly with low-income consumers, successfully growing traffic share with this group for the first time in over a year."
